N-[3-(aminomethyl)pheny]cinnamamide

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 肉桂酸及其衍生物
• 英文名称: N-[3-(aminomethyl)pheny]cinnamamide
• 英文别名: (E)-N-[3-(aminomethyl)phenyl]-3-phenylprop-2-enamide
• 化学式: C₁₆H₁₆N₂O
• 分子量: 252.316
• InChiKey: OOKFMGTWOWCFGC-MDZDMXLPSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  19.0
• 可旋转键数：
  4.0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  55.12
• 氢给体数：
  2.0
• 氢受体数：
  2.0

反应信息

• 作为反应物：
  描述：

  1-萘甲酸 、 N-[3-(aminomethyl)pheny]cinnamamide 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 以26.7%的产率得到(E)-N-(3-cinnamamidobenzyl)-1-naphthamide
  参考文献：
  名称：

  Identification of SENP1 inhibitors through in silico screening and rational drug design

  摘要：

  The small ubiquitin-related modifier (SUMO)-specific proteases (SENPs) catalyze the deconjugation of SUMO from their substrate proteins. SENP1 which is the most studied isoform is closely related to many cancers such as prostate cancer and colon cancer, thus representing a potential therapeutic target for cancer treatment. In the present study, we identified eleven SENP1 inhibitors representing a variety of scaffolds through in silico screening. Based on these scaffolds, a series of new compounds were designed and synthesized in order to improve their SENP1 inhibitory potency. As a result, compounds with IC50 as low as 3.5 mu M (compound 13m) were obtained and a preliminary structure-activity relationship was discussed. (C) 2016 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2016.06.018

文献信息

• Identification of SENP1 inhibitors through in silico screening and rational drug design
  作者：Yaxue Zhao、Zhongli Wang、Jianchen Zhang、Huchen Zhou

  DOI：10.1016/j.ejmech.2016.06.018

  日期：2016.10

  The small ubiquitin-related modifier (SUMO)-specific proteases (SENPs) catalyze the deconjugation of SUMO from their substrate proteins. SENP1 which is the most studied isoform is closely related to many cancers such as prostate cancer and colon cancer, thus representing a potential therapeutic target for cancer treatment. In the present study, we identified eleven SENP1 inhibitors representing a variety of scaffolds through in silico screening. Based on these scaffolds, a series of new compounds were designed and synthesized in order to improve their SENP1 inhibitory potency. As a result, compounds with IC50 as low as 3.5 mu M (compound 13m) were obtained and a preliminary structure-activity relationship was discussed. (C) 2016 Elsevier Masson SAS. All rights reserved.